TX-MARY-KAY
18.7.2022 21:17:09 CEST | Business Wire | Press release
Mary Kay Inc. a leading corporate advocate of women’s empowerment and entrepreneurship, continued its decades-long support of education and academic research with the announcement of the 2022 winners of the Mary Kay Doctoral Dissertation and Doctoral Dissertation Proposal Awards at the Academy of Marketing Science (AMS) Annual Conference held May 25 – 27 in Monterey, California. For nearly 30 years, the global beauty company has awarded these annual grants to doctoral candidates in marketing, giving them the opportunity to showcase their successfully defended dissertations in front of their peers. Winners are determined based on their final presentations at the AMS Annual Conference.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220718005732/en/
Submissions are open to doctoral students covering any marketing-related topics, methodology, and research interests worldwide. The finalists of the 2022 Mary Kay Doctoral Dissertation and Doctoral Dissertation Proposal Awards are:
Mary Kay Doctoral Dissertation Proposal Award Finalists
- Winner – Ali Anwar, PhD Candidate, Wilfrid Laurier University (Canada) – “Sales Enablement in Young Ventures: Essays on the Role of Resilience and Internal Social Capital in coping with Adverse Disruptions”
- 1st Runner Up – Alexander Fulmer, PhD Candidate, Yale University – “Questioning the Intuitive Preference for Intentionality”
- 2nd Runner Up – Jen Riley, PhD Candidate, Kennesaw State University – “Evaluating the Impact of Sales Technology on Professional Sales: An Analysis of Social Selling Effectiveness”
2022 Mary Kay Doctoral Dissertation Award Finalists
- Winner – Ishita Chakraborty, PhD, Yale University – “Attribute Sentiment Scoring with Online Text Reviews: Accounting for Language Structure and Missing Attributes”
“The Academy of Marketing Science Mary Kay Dissertation and Dissertation Proposal Awards provide unique opportunities for marketing professionals to showcase their work and receive constructive feedback from their peers, which is vital to their professional growth,” said Sheryl Adkins-Green, Chief Marketing Officer at Mary Kay Inc. “At Mary Kay, we remain committed to providing platforms for educational and career advancement, as well as professional development. We are proud to support these talented marketing professionals and their contributions to the marketing field.”
“It is becoming increasingly more competitive to have your work published in the major Marketing journals, and to have the opportunity to receive feedback from leading Marketing scholars before submission is invaluable,” said Julie Moulard, Immediate Past President (as of June 1) of Academy of Marketing Science. “Mary Kay’s Dissertation Awards provide a critical platform for these marketing professionals to have their work reviewed and fine-tuned to better their chances of successfully publishing research findings in credible Marketing journals, which ultimately benefits their overall academic reputation and credibility.”
For more information about the Academy of Marketing Science Mary Kay Dissertation Awards, click here .
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty company in 1963 with one goal: enriching women’s lives. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. As an entrepreneurship development company, Mary Kay is committed to empowering women on their journey through education, mentorship, advocacy, networking, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in enriching lives today for a sustainable tomorrow, partnering with organizations from around the world focusing on promoting business excellence, supporting cancer research, advancing gender equality, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Learn more at marykayglobal.com , find us on Facebook , Instagram , and LinkedIn , or follow us on Twitter .
About The Academy of Marketing Science
The Academy of Marketing Science is a non-profit, international, scholarly, professional organization. It is dedicated to promoting high standards and excellence in the creation and dissemination of marketing knowledge and the furtherance of marketing practice through a role of leadership within the discipline of marketing around the world. The Academy is committed to the highest ethical standards and collegiality in the pursuit of this mission.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220718005732/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom